Elocalcitol

Drug Profile

Elocalcitol

Alternative Names: BXL 628; Vitamin D3 analogue - BioXell

Latest Information Update: 30 Dec 2011

Price : $50

At a glance

  • Originator Roche
  • Developer BioXell SpA; Cosmo Pharmaceuticals
  • Class Dihydroxycholecalciferols; Small molecules; Urologics; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Intercellular signalling peptide and protein inhibitors; Interleukin 8 inhibitors; Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Male infertility
  • Discontinued Benign prostatic hyperplasia; Interstitial cystitis; Overactive bladder; Prostatitis

Most Recent Events

  • 12 Mar 2010 BioXell SpA has been acquired and merged into Cosmo Pharmaceuticals
  • 08 Apr 2009 Top-line efficacy data from a Phase-IIb trial in Overactive bladder released by BioXell SpA
  • 17 Dec 2008 BioXell SpA completes enrolment in its Phase-IIb trial for Overactive bladder in the EU and Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top